Atala Financial Inc Acquires Shares of 6,289 Hims & Hers Health, Inc. (NYSE:HIMS)

Atala Financial Inc acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 6,289 shares of the company’s stock, valued at approximately $152,000.

A number of other institutional investors have also recently bought and sold shares of HIMS. Principal Financial Group Inc. grew its stake in Hims & Hers Health by 102.0% in the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock valued at $5,349,000 after purchasing an additional 146,621 shares during the period. State of New Jersey Common Pension Fund D grew its stake in Hims & Hers Health by 30.1% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 123,587 shares of the company’s stock valued at $2,276,000 after purchasing an additional 28,600 shares during the period. Los Angeles Capital Management LLC grew its stake in Hims & Hers Health by 40.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 40,353 shares of the company’s stock valued at $743,000 after purchasing an additional 11,686 shares during the period. Victory Capital Management Inc. grew its stake in Hims & Hers Health by 164.9% in the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock valued at $950,000 after purchasing an additional 32,108 shares during the period. Finally, Royce & Associates LP grew its stake in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after purchasing an additional 49,500 shares during the period. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of recent analyst reports. Citigroup restated a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research note on Tuesday, February 25th. Piper Sandler increased their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, BTIG Research assumed coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $37.23.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $33.10 on Friday. The stock’s 50-day simple moving average is $38.49 and its 200 day simple moving average is $28.04. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of 75.24 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the sale, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 4,213 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $29.98, for a total value of $126,305.74. Following the completion of the sale, the chief financial officer now directly owns 128,365 shares in the company, valued at approximately $3,848,382.70. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 969,191 shares of company stock valued at $34,005,375 in the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.